In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...

In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Bio-Techne (TECH) is back in focus after institutional ...

The latest price target for Bio-Techne (NASDAQ:TECH) was reported by Wells Fargo on May 30, 2025. The analyst firm set a price target for $59.00 expecting TECH to rise to within 12 months (a possible ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life sciences sector.

(RTTNews) - Gemini Bioproducts, LLC, a supplier of cell culture reagents and process liquids and healthcare private equity firm BelHealth Investment Partners, LLC announced acquisition of selected ...

Shares of Bio-Techne Corp. slipped 4.01% to $48.81 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 1.01% to 6,699.38 and the Dow ...

Madison Investments, an investment advisor, released its fourth-quarter 2025 investor letter for “Madison Mid Cap Fund”. A copy of the letter can be downloaded here. The Russell Midcap Index ended an ...